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Summary
Platelet-rich plasma (PRP) is a new powerful bio-
logical tool in sports medicine, when used to treat
tendon, ligament and muscle injuries. PRP is a
fraction of autologous whole blood containing an
increased number of platelets and a wide variety
of cytokines that can improve and accelerate the
healing of various tissues. 
An analysis of the literature shows promising pre-
clinical results for PRP treatment, but there is a
lack of solid clinical proof to support its use in
sports medicine, and in fact, clinical findings on
individual responses to PRP treatment are contra-
dictory. These contradictions may be due to in-
terindividual differences in the presence of single
nucleotide polymorphisms (SNPs) in genes relat-
ed to PRPs and/or their receptors. These SNPs
can determine a greater or lesser response to this
treatment and consequently a shorter or longer
recovery time. 
We have focused our attention in the study of
genes related to PRP with the aim to develope a
genetic profile that will identify the individuals
and injuries most likely to benefit from PRP
treatment. 
KEY WORDS: musculoskeletal soft-tissue injuries, single
nucleotide polymorphisms, platelet-enriched proteins,
growth factors.
Introduction
Since PRP was first introduced as topical adjuvant
therapy to treat chronic leg ulcers in the late 1980s1,
its use has been extended to many fields of medi-
cine, such as dermatology, ophthalmology2, den-
tistry3 and maxillofacial surgery3. Recently, PRP in-
jections have emerged as a fashionable non-inva-
sive treatment also in sports medicine4, where they
are used to treat acute or chronic tendinopathy5-8
and muscle9,10 and ligament11,12 injuries, because
PRP provides numerous growth factors needed to
promote the healing process. Despite the wide use
of PRP injections, research into their clinical effi-
ciency is still in its beginings, and an analysis of the
literature reveals a lack of solid evidence supporting
the use of PRP13. More studies are required to con-
firm preliminary results and provide stronger scien-
tific evidence.
Tissue repair in musculoskeletical injuries is often a
slow and sometimes incomplete process. Muscu-
loskeletical injuries have a great impact on athletes –
especially elite athletes – and a rapid recovery of full
efficiency and return to competition is of primary im-
portance14. The search for a minimally invasive treat-
ment of these injuries is of great importance, espe-
cially in the world of sports. 
The use of growth factors is thought to be useful in
clinical practice15 because it promotes rapid healing
with a high-quality tissue and allows an early and
safe return to unrestricted activity. Platelet-rich plas-
ma (PRP) is a simple and minimally invasive way to
obtain a natural concentration of autologous growth
factors, including IGF, EGF, TGFb1, FGF216, as
growth factors are critical for wound healing. PRP is
currently being widely experimented in different
fields of medicine due to its ability to help the regen-
eration of tissue with low healing potential. The
analysis of the literature17,18 shows promising pre-
clinical results but contradictory clinical findings in
individual response to treatment in sports injuries.
These contradictions may be due to interindividual
differences in the presence of single nucleotide
polymorphisms (SNPs) in genes related to PRP
and/or their receptors and that these SNPs can de-
termine a greater or lesser response to treatment
and consequently a shorter or longer recovery time.
A SNP is a DNA sequence variation which occurs
when a single nucleotide in the genome differs in
similar chromosomes in a given individual. SNPs in
genes related to the biology of muscles19,20, ten-
dons21-23 and ligaments24 have been associated with
injury recovery time25,26.
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Questions about PRPs and hypothesis
In recent years there has been an increasing re-
search into genes related to the healing of soft tis-
sue27. SNPs in genes that codify for these growth fac-
tors could influence treatment effectiveness and ex-
plain differences observed in recovery times. It is im-
portant to examine the maximum possible number of
SNPs in PRP-related genes in order to identify a
gene signature that promotes tissue healing in order
to determine an objective measurement of an individ-
ual’s predisposition to recovery after this kind of treat-
ment. Moreover it is important to know if the presence
of these SNPs correlates with a greater or lesser de-
gree of injury repair capability and/or with a short or
long recovery time and, finally to identify a genetic
profile for the selection of individuals who will re-
spond more quickly to treatment following muscu-
loskeletal soft tissue injuries and to identify the type
of injury (muscle, tendon or ligament) in which PRP
treatment is most effective.
Why analyze PRPs? 
Cytokines and growth factors are soluble signaling
proteins affecting the process of normal wound heal-
ing28. Cytokines control the inflammatory phase that
clears cellular and extracellular matrix debris. The in-
flammatory stage is guided by inflammatory cells that
release multiple cytokines, including IL-1. Cytokines
induce expression of fibroblasts and endothelial cells
and cause macrophage expression of more cy-
tokines. As inflammation reduces, wound repair takes
place29. Early wound repair includes three simultane-
ous steps (epithelization, neoangiogenesis and pre-
matrix formation) and is controlled by growth factors
(platelet-derived growth factor [PDGF], keratinocyte
growth factor, and transforming growth factor β). Fi-
nally, during the later wound repair, TGFb up regu-
lates MMPs inhibitors to help matrix construction by
driving collagen expression.
Due to the high implication of these molecules in this
important process, we think it is important to analyze
the presence of SNPs in all of these factors to eluci-
date if these polymorphisms could affect the final pro-
tein function. 
The most commonly studied platelet proteins include
platelet-derived growth factor (PDGF), transforming
growth factor (TGF-β), platelet-derived epidermal
growth factor (PDEGF), vascular endothelial growth
factor (VEGF), insulin-like growth factor 1 (IGF-1), fi-
broblastic growth factor (FGF), epidermal growth fac-
tor (EGF)30 (Tab. 1). 
Future Goals
The use of PRP treatment has increased in a some-
what random manner without real knowledge of its ef-
fectiveness, since contradictory results have been re-
ported. The study of these SNPs may shed light on
the tendency of certain individuals to recover more
rapidly and more completely from injuries and may
help identify individuals with an enhanced injury re-
pair system. 
Now our research group is investigating this issue
with a group of professional football players from the
Spanish League with promising results and shortly
we will be able to increase our sample size with play-
ers from European teams. 
Future findings will provide a tool to identify the indi-
viduals and injuries most likely to benefit from PRP
treatment and thus improve not only recovery time
but also restitutio ad integrum by reducing the risk of
re-injury and scars production.
The study meets the ethical standards of the Journal31.
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Table 1. Growth factors and their associated role.
GROWTH FACTOR POSSIBLE ROLE
PDGF Angiogenesis 
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PDEGF Cellular proliferation and 
differentiation
VEGF Vascularization
IGF-1 Stimulates protein 
synthesis
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